Statin use and risk of diabetes mellitus in postmenopausal women

Bibliography

• Culver AL, Ockene IS, Balasubramanian R et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med. 172(2), 144–152 (2012).
   Google Scholar
• Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716), 735–742 (2010). This meta-analysis found that statin use was associated with a 9% increased risk of incident diabetes mellitus (DM), but the risk was low compared with the reduction in coronary events. Furthermore, in absolute terms, only one new incidence of DM was reported for 255 statin-treated patients for a 4-year period.
   Google Scholar
• Waters DD, Ho JE, DeMicco DA et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J. Am. Coll. Cardiol. 57(14), 1535–1545 (2011)
   Google Scholar
• Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing Type 2 diabetes: a meta-analysis. Diabetes Care 32(10), 1924–1929 (2009).This meta-analysis reported that statin treatment was related to a 13% increased risk of incident DM, but the risk was lower (i.e., 6%) when the WOSCOPS trial was included
   Google Scholar
• Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother. 11(12), 1965–1970 (2010).The authors comment on the effects of different hypolipidemic drugs on incident DM
   Google Scholar
• Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann. Intern. Med. 127(8 Pt 2), 757–763 (1997)
   Google Scholar
• Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins – clinical evidence. Curr. Pharm. Des. 15(5), 479–489 (2009)
   Google Scholar
• Kowalski J, Barylski M, Banach M, Grycewicz J, Irzma?ski R, Pawlicki L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J. Cardiovasc. Pharmacol. 48(4), 143–147 (2006)
   Google Scholar
• Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr. Opin Lipidol. 22(6), 460–466 (2011)
   Google Scholar
• Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS. Do statins beneficially or adversely affect glucose homeostasis? Curr. Vasc. Pharmacol. 8(5), 612–631 (2010)
   Google Scholar
• Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103(3), 357–362 (2001)
   Google Scholar
• Mancia G, Bombelli M, Facchetti R et al. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J. Hypertens. 26(8), 1602–1611 (2008)
   Google Scholar
• Rysz J, B?aszczak R, Banach M et al. Evaluation of selected parameters of the antioxidative system in patients with Type 2 diabetes in different periods of metabolic compensation. Arch. Immunol. Ther. Exp. (Warsz). 55(5), 335–340 (2007)
   Google Scholar
• Karagiannis A, Tziomalos K, Anagnostis P et al. The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. Curr. Vasc. Pharmacol. 8(6), 792–803 (2010)
   Google Scholar
• Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr. Vasc. Pharmacol. 8(6), 733–741 (2010)
   Google Scholar
• Katsiki N, Banach M. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med. (2012) (In press)
   Google Scholar
• Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and new-onset diabetes mellitus-a matter for debate. Nat. Rev. Endocrinol. 8(3), 133–134 (2012)
   Google Scholar